

Clovis Oncology, Inc.
Form 8-K
June 03, 2013

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): **June 3, 2013**

Clovis Oncology, Inc.

(Exact name of registrant as specified in its charter)

Delaware **001-35347** **90-0475355**
(State or other jurisdiction) (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
2525 28th Street, Suite 100

Boulder, Colorado **80301**
(Address of principal
executive offices) (Zip Code)

Registrant's telephone number, including area code: **(303) 625-5000**

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On June 3, 2013, Clovis Oncology, Inc. issued a press release announcing initial clinical data from the Phase I portion of its ongoing Phase I/II clinical study of CO-1686, the company's novel, oral, targeted covalent (irreversible) inhibitor of mutant forms of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer in patients with initial activating EGFR mutations as well as the dominant resistance mutation T790M. Four RECIST partial responses in T790M positive patients have been observed to date, and the maximum tolerated dose has not yet been reached. These initial Phase I results are being presented for the first time on Tuesday, June 4 at a poster session during the American Society of Clinical Oncology (ASCO) Annual Meeting 2013 in Chicago.

A copy of the press release is being filed herewith as Exhibit 99.1 and the information contained therein is incorporated by reference into this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Number and Description

99.1 Press Release, dated June 3, 2013.

- 2 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CLOVIS ONCOLOGY, INC.

June 3, 2013 By: /s/ Erle T. Mast
 Name: Erle T. Mast
 Title: Executive Vice President and Chief Financial Officer

- 3 -

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release, dated June 3, 2013.

- 4 -